This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Alimera Sciences Honored With The 2010 Southeast Bio Deal Of The Year: Strategic Transaction Award

ATLANTA, Nov. 5, 2010 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today accepted the 2010 Southeast BIO (SEBIO) Deal of the Year: Strategic Transaction award at a ceremony held at the conclusion of the organization's 12 th Annual Investor Forum. The SEBIO Annual Investor Forum is the region's premier life sciences venture capital conference and attracts an estimated 400 attendees. Rick Eiswirth, Alimera's chief operating officer and chief financial officer, accepted the award on behalf of the company.

"As one of the fastest growing industry hubs in the country, Southeast BIO is in a unique position to recognize some of the nation's leading life sciences companies," remarked Jennifer Moore, Ph.D., executive director of SEBIO. "Alimera is an outstanding example of a sustainable and innovative business, and we are delighted to honor their contributions today among industry peers and venture capital investors."

Alimera was selected for this award as a result of the company's initial public offering and venture debt raise totaling more than $100 million earlier this year. On April 21, 2010, Alimera completed its initial public offering of 6.55 million shares of common stock, resulting in net proceeds to Alimera of approximately $68.4 million. Shares of Alimera common stock began trading on the NASDAQ Global Market under the symbol "ALIM" on Thursday, April 22, 2010. In October, 2010, Alimera obtained a $32.5 million senior secured credit facility to help fund its working capital requirements.

"Alimera is proud to be recognized by SEBIO for our strategic financial transactions and as a driving force in the region's life sciences industry," said Eiswirth. "We hope our investors will continue to benefit from our recent progressive strides, namely the positive results from our Phase 3 (FAMEā„¢) clinical trials of our lead product candidate, Iluvien®, for patients with diabetic macular edema (DME), which is now under Priority Review by the FDA."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs